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The utility of cutaneous biopsies in directing the management of posthematopoietic cell transplantation
(HCT) eruptions remains uncertain. We retrospectively analyzed 439 consecutive HCT procedures for
malignant hematologic disorders performed at our institution between January 2005 and December 2012;
192 patients underwent 430 cutaneous biopsies. The clinical and dermatopathologic diagnosis differed in 240
cases (56%). Biopsy results led to a change in therapy in 69 (16%) episodes. Seventeen of 69 management
changes occurred in response to a clinical diagnosis of graft-versus-host disease and resulted in augmentation
of systemic immunosuppression. The management was modiﬁed with similar frequencies with respect to
concordance or discordance between the clinical and histopathologic diagnosis (P ¼ .51). We used classiﬁ-
cation and regression tree (CART) analysis, a decision-modeling technique, to predict the biopsy yield as
expressed by impact on clinical management in the allogeneic and autologous setting. The models were
cross-validated and then tested against a validation subset, and they maintained a high negative predictive
value and high speciﬁcity. Although skin biopsies may not be mandatory for either diagnostic or therapeutic
reasons, in carefully chosen circumstances, this procedure can yield extremely important data. We believe
a prospective study should be undertaken to evaluate current practice data and to validate our decision tree
models.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION sources (blood versus marrow); utilization of alternative
Hematopoietic cell transplantation (HCT) has been
established as the treatment of choice for a variety of
malignant and nonmalignant disorders [1]. This modality
remains plagued by potentially severe complications,
including infection, bleeding, visceral organ dysfunction,
relapse of the primary disorder, as well as both acute and
chronic graft-versus-host disease (GVHD). Not surprisingly,
in the course of the treatment, patients develop cutaneous
eruptions that can pose diagnostic challenges to clinicians.
These varied disorders may have overlapping features and
may be difﬁcult to discern despite classiﬁcation according to
consensus guidelines [2]; they include acute and chronic
GVHD, drug eruptions, viral exanthems, acral erythema, toxic
epidermal necrolysis, engraftment syndrome, radiation
dermatitis, erythema multiforme, and fungal infections [3].
Their clinical management varies widely enough that
obtaining a correct diagnosis is essential. To resolve these
diagnostic uncertainties, transplanters often turn to histo-
pathologic evaluation for assistance.
Two decades ago, we reported the signiﬁcance of cuta-
neous biopsies in adult patients admitted for HCT between
1986 and 1989 at our center [4]. Since then, the approach to
HCT has changed signiﬁcantly with the use of different graftedgments on page 1209.
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13.05.006donor transplants including matched unrelated donor
(MUD), umbilical cord blood (UCB) and haploidentical
grafts; lesser-intensity conditioning regimens; novel and
improved supportive care approaches including new anti-
biotics and cellular therapies; and better diagnostic tech-
niques. New clinical syndromes also are recognized at
increased frequency, including autologous GVHD [5]. In this
new environment, the impact of skin biopsies on the
management of post-HCT cutaneous eruptions remains
a subject of debate. To update and re-evaluate our experi-
ence, we retrospectively evaluated 439 consecutive patients
who underwent HCT procedures.PATIENTS AND METHODS
We performed this retrospective analysis in consecutive adult patients
undergoing HCT procedures for malignant hematologic conditions between
January 2005 and December 2012 at University Hospitals Case Medical
Center, a teaching and referral hospital of Case Western Reserve University,
Cleveland, Ohio. The patients had undergone either an autologous or allo-
geneic HCT using peripherally collected hematopoietic cells or occasionally
bone marrow grafts; allogeneic transplant grafts were obtained from
matched related donors, MUD, and UCB. The preparative regimens utilized
were reduced-intensity, nonmyeloablative, and myeloablative conditioning.
The patients were followed for 1 year from the date of transplant (T0), or
through the last available entry, whichever came ﬁrst. The transplant
attending physician evaluated all skin eruptions and made the decision to
refer to the Dermatology service for consultation. In patients withmore than
1 episode of rash, each was determined to be a distinct event in terms of its
clinical characteristics and timing. The Institutional Review Board at
University Hospitals Case Medical Center formally approved this
investigation.
Biopsy specimens were obtained using standard procedures, by means
of intradermal anesthesia with lidocaine hydrochloride. Portions of all bio-
psied tissue were ﬁxed immediately in 10%, then embedded, sectioned, andTransplantation.
Table 1
Levels of Agreement between the Histopathologic and Clinical Diagnosis
Concurrent Discordant Noncontributory
Histopathology
demonstrates
speciﬁc diagnostic
features or features
consistent with,
but not diagnostic,
of the clinical
diagnosis.
The histologic results
supported a different
diagnosis, or a
deﬁnitive histologic
result was not
obtained, but the
suspected results differ
completely from the
clinical diagnosis.
Histopathology fails
to support or
exclude the
clinical diagnosis.
O. Paun et al. / Biol Blood Marrow Transplant 19 (2013) 1204e1209 1205stained with hematoxylin-eosin. Additional stains were at the discretion of
the dermatopathologist.
Clinical data were obtained using the archived paper charts and the
hospital electronic medical records system. Histologic results were obtained
from the ofﬁcial report entered by a dermatopathologist, who had been
provided the clinical history and impression. Throughout the study period 2
dermatopathologists were responsible for 95% of the biopsies, which
decreases the inherent variability associated with multiple readers. The
prebiopsy diagnosis was that recorded by the primary care team, while the
ﬁnal diagnosis was the histologic characterization of the dermatopatholo-
gist. The level of agreement between the histologic result and the clinical
diagnosis is detailed in Table 1. A change in patient therapy was deﬁned as
the addition or discontinuation of a systemic or topical medication as
a direct consequence of learning the histopathologic results.
Statistical Analysis
Logistical regression was used to identify the factors signiﬁcantly asso-
ciated with a change of management. The predictive values of age, gender,
diagnosis, total body irradiation, graft, conditioning, and body locationwere
ﬁrst estimated in univariate analysis (simple logistic regression), then
further estimated using multivariable logistic regression. Odds ratio for
change of management between groups was calculated. All tests are 2-sided
and P values  .05 are considered statistically signiﬁcant.
Classiﬁcation and regression tree (CART) analysis was used to develop
an algorithm to predict the subpopulation prone to beneﬁt from biopsies as
expressed by changes in management. This nonparametric decision treeTable 2
Baseline Characteristics of Patients
Characteristic Biopsy
(n ¼ 192)
No Biopsy
(n ¼ 247)
P Value
Age (median,
range), y
55 (18 to 74) 57 (18 to 73) P ¼ .16
Male gender 121 (63) 136 (55) P ¼ .09
Graft source P < .0001
Autologous 32 (17) 200 (81) Allogeneic
population is
not homogenous
P ¼ .02
MRD 47 (24) 22 (9)
MUD 42 (22) 9 (4)
UCB 71 (37) 16 (6)
Intensity P < .0001
Autologous 32 (16) 200 (81) Allogeneic
population is
homogenous
P ¼ .35
MA 63 (33) 15 (6)
NMA 97 (51) 32 (13)
TBI (allograft only) 37 (41) 24 (51) P ¼ .3
Disease P ¼ .001
ALL 23 (12) 4 (2)
AML 76 (40) 38 (20)
PCM 21 (11) 101 (53)
NHL 29 (15) 79 (41)
Other* 43 (22) 25 (13)
ALL indicates acute lymphocytic leukemia; AML, acute myeloid leukemia;
PCM, plasma cell myeloma; NHL, non-Hodgkin lymphoma; MRD, matched
related donor; MUD, matched unrelated donor; UCB, umbilical cord blood;
MA, myeloablative conditioning; NMA, nonmyeloablative and reduced-
intensity conditioning; TBI, total body irradiation.
Data are presented as n (%) unless otherwise indicated.
* Other includes chronic lymphocytic leukemia, chronic myeloid
leukemia, myeloﬁbrosis, myelodysplastic syndrome, aplastic anemia and
Hodgkin lymphoma.learning technique is based on a categorical dependent variable, with
a collection of rules extracted from the variables in the modeling data set
selected for the best split that differentiates the observations. Each branch of
the tree ends in a terminal node, and each observation falls into 1 and
exactly 1 terminal node. The tree construction continues until the number of
cases reaching each leaf is small (we chose <10) or the leaf is sufﬁciently
homogeneous (we chose 1% of the deviance of the root node). The terminal
node presents the retrospective yield of the cutaneous biopsy and allows the
clinician to add to the pretest probability of change of clinical management.
The model was both cross-validated within the training set and tested on
a validation subset.RESULTS
Patient Characteristics
Clinical characteristics of all 439 patients who underwent
transplantation are presented in Table 2. A total of 232
patients underwent autologous HCT and 207 patients
underwent allogeneic HCT. Allogeneic transplant sources
were matched related donors (n ¼ 69), MUD (n ¼ 51), and
UCB (n ¼ 87). In the allogeneic group, 78 patients received
myeloablative conditioning, whereas 129 subjects received
either nonmyeloablative or reduced-intensity conditioning
regimens. A total of 61 patients received total body irradia-
tion. The major diseases prompting HCT included acute
lymphoblastic leukemia, acutemyeloid leukemia, plasma cell
myeloma, and non-Hodgkin lymphoma; other diagnoses
included aplastic anemia, chronic lymphocytic leukemia,
chronic myeloid leukemia, myeloﬁbrosis, myelodysplastic
syndrome and Hodgkin lymphoma. The group that under-
went cutaneous biopsy after HCT and the group that was
spared the procedure were homogenous with regard to age,
gender, and use of total body irradiation. Recipients of an
allograft were signiﬁcantly more likely to undergo biopsy,
especially in the case of a nonmatched related donor graft
(P¼ .015), whereas the majority of autologous HCT recipients
are clustered in the “no biopsy” category. The groups were
also separated by the intensity of the preparative regimen
and by malignant disease.
Because of the inherent difﬁculties associated with
retrospective chart reviews, we were unable to compile dataTable 3
Speciﬁc Histologies of the Cutaneous Eruptions
Diagnosis n
Graft-versus-host disease 149
Nonspeciﬁc 122
Drug eruption 44
Cutaneous infection 22
Inﬂammatory 20
Cutaneous manifestation of systemic infection 9
Leukemia/lymphoma cutis 6
Other 55
Urticaria 12
Purpura 7
Nonmelanoma skin cancer 5
Hemorrhage 4
Eczema 3
Arthropod assault 3
Seborrheic keratosis 2
Acantholysis 2
Lichenoid 2
Postinﬂammatory hyperpigmentation 2
Ulcer 2
Scar 2
Angiokeratoma 1
Compound nevus 1
Hydroadenoma 1
Necrosis 1
Scleromyxedema 1
Sweet syndrome 1
Figure 1. Classiﬁcation and regression tree analysis for patients undergoing allogeneic HCT. HCT indicates hematopoietic cell transplant; ALL, acute lymphocytic
leukemia; AML, acute myeloid leukemia; PCM, plasma cell myeloma; NHL, non-Hodgkin lymphoma; TBI, total body irradiation; MRD, matched related donor; MUD,
matched unrelated donor; UCB, umbilical cord blood; MA, myeloablative conditioning; NMA, nonmyeloablative/reduced-intensity conditioning.
O. Paun et al. / Biol Blood Marrow Transplant 19 (2013) 1204e12091206
Figure 2. Classiﬁcation and regression tree analysis for patients undergoing autologous HCT. AML indicates acute myeloid leukemia; PCM, plasma cell myeloma; NHL,
non-Hodgkin lymphoma.
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gated with a biopsy.Clinical Features of the Episode of Biopsied Cutaneous
Eruptions
The median (range) time from HCT to biopsy was
44.5 (2 to 356) days with 66% of the rashes occurring within
the ﬁrst 100 days fromHCTand 23% occurringwithin the ﬁrst
21 days. The median time to biopsy for the 138 rashes
occurring after day 100 was 205 days. Ninety percent of all
biopsies were performed in the allogeneic setting and in 60%
of the patients who received total body irradiation. At the
time of biopsy, the majority of patients were receiving an
antimicrobial agent (antiviral, antibacterial, antifungal, or
a combination of the above); in addition, the majority of the
patients were taking an immunosuppressive agent.Histopathologic Diagnosis and Relationship to Clinical
Diagnosis
A total of 430 biopsies were performed in 192 (44%) of the
439 HCT recipients. There were no documented complica-
tions of the procedure. The most common histologic result
was GVHD (149 cases, 35%), followed by nonspeciﬁc ﬁndings
(122 cases, 28%). The speciﬁc histologies are listed in Table 3.The clinical and histopathologic diagnosis differed in 240
episodes (56%). Cutaneous biopsy speciﬁcity and accuracy
were higher than 90% for drug eruptions, lymphoma/
leukemia cutis, skin and soft tissue infections, cutaneous
manifestations of systemic infection (eg, viral exanthems),
inﬂammation, and nonmelanoma skin cancer. The overall
sensitivity and speciﬁcity for GVHD were 91% and 55%,
respectively, in line with the previous data showing overall
low speciﬁcity for GVHD [6].Changes in Therapy as a Result of Biopsy
Examples of changes in therapy prompted by biopsy are
listed in Table 3. Biopsy led to management modiﬁcations in
69 (16%) of the 430 rashes evaluated. Most therapy changes
(42 of the 61) occurred in the setting of suspected GVHD; in
24 out of these 42 cases, systemic immunosuppression was
reinitiated or augmented. Wewere able to conﬁrm 2 cases of
discontinuation of immunosuppressive medication because
of lack of GVHD features in the specimen. Biopsy results led
to drug (antibiotic) discontinuation in 8 cases related to drug
eruptions. We documented disease recurrence (lymphoma/
leukemia) in 5 instances, all of which led to a change in
clinical management. We found 10 documented cases of an
infectious etiology on biopsy results. The management
ranged from reinitiation of systemic therapy to the surgical
Table 4
Examples of Changes in Management Resulting from Histopathologic
Evaluation
Clinical
Impression
Histologic Result Therapy Change
Drug eruption Drug eruption Drug discontinued
Drug eruption GVHD Drug restarted
Drug eruption Nonspeciﬁc Drug discontinued
GVHD GVHD vs. drug
eruption
Intravenous antibiotic switch
GVHD Infection Systemic antiviral added
GVHD Skin infection Systemic antifungal added
GVHD GVHD Systemic immunosuppression
augmented
GVHD Drug eruption Immunosuppression taper
GVHD Drug eruption Drug discontinued
GVHD Other (urticaria) Immunosuppression
discontinued
GVHD Nonspeciﬁc Referral to immunology for
persistent dermatosis
Infection Viral infection vs.
drug eruption
Systemic antiviral therapy
initiated
Infection Lymphoma/leukemia
cutis
Antineoplastic chemotherapy
initiated
Infection Infection Speciﬁc antibiotherapy
Infection Infection Surgical debridement of
ecthyma granulosum
Infection GVHD Systemic immunosuppression
restarted
Inﬂammatory
(dermatitis)
Drug eruption vs.
GVHD
Systemic steroids added
Leuk/lymph cutis Leuk/lymph cutis Chemotherapy/radiation
initiated
Leuk/lymph cutis Leuk/lymph cutis Change in goals of care
(hospice)
Nonspeciﬁc Fungal infection Systemic antifungal therapy
Nonspeciﬁc GVHD vs. drug
eruption
Systemic steroids added
Skin infection Skin infection Topical antifungal added
GVHD indicates graft-versus-host disease; Leuk/lymph, leukemia or
lymphoma.
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therapy occurred with similar frequencies with respect to
concordance or discordance between the clinical and histo-
pathologic diagnosis (P ¼ .51).Factors Associated with Change in Management
In an effort to identify patient characteristics associated
with a higher yield of cutaneous biopsy examination, we
looked at the contribution of each variable to the rate of
management changes through univariate analysis. It
appeared that a cutaneous eruption after autologous HCT
had a higher impact on management, mostly involving
antibiotic modiﬁcation (odds ratio [OR] 2.56, P ¼ .009);
along the same lines is the statistical signiﬁcance of a diag-
nosis of plasma cell myeloma or non-Hodgkin lymphoma
(OR ¼ 1.95, P ¼ .03). The body location of the rash is also of
signiﬁcance, as involvement of the chest (OR ¼ 1.95, P ¼ .04)
and face (OR ¼ 3.3, P ¼ .016), but not the upper extremitiesTable 5
Characteristics of the Classiﬁcation Trees
Total
Nodes
Terminal
Nodes
Depth
Level
Variab
Allogeneic decision model tree  training 18 9 5 Time f
impAllogeneic decision model tree  validation
Autologous decision model tree 9 5 3 Age, d
PPV indicates positive predictive value; NPV, negative predictive value; TBI, total b(OR¼ .4, P¼ .008) was prone to impact the management. We
did not observe statistically signiﬁcant differences based on
use of total body irradiation, type of allograft donor, or
gender. Multivariable logistic regression used to identify
predisposing factors did not reach statistical signiﬁcance.
Classiﬁcation and Regression Tree (CART) Analysis
Figures 1 and 2 depict the corresponding allogeneic and
autologous HCT classiﬁcation and regression analysis trees.
To allow for the different behavior of early (within 100 days
from T0) and late (after T100) eruptions, the allogeneic tree
was initially subdivided into an “early” and a “late” compo-
nent. The allogeneic data set was divided into a training set
(292 biopsies, 75%) and a validation set (95 biopsies, 25%)
through a randomization procedure. The allogeneic tree was
build and internally cross-validated using the training set,
and further tested in the validation set. Because of the rela-
tively low number of biopsies in the autologous setting, the
autologous tree was cross-validated internally only, using
a 10-fold pattern.
Table 5 lists the general characteristics of the decision
trees; it should be noted that the models have a high nega-
tive predictive value, as well as moderate speciﬁcity and
sensitivity. Although the validation test maintains the high
negative predictive value and speciﬁcity, it lacks sensitivity,
which may be attributable to the relatively small sample size
(95 biopsies).
An example for clinical use of the decision tree is as
follows: a 65-year-old female who undergoes autologous
HCT and develops a cutaneous eruption clinically suggestive
of an infectious process has a 71.5% chance of a contributory
histopathologic result (5 out of 7 patients in our cohort). On
the other hand, if the patient is a male with acute myeloid
leukemia, no total body irradiation, and develops a rash of
unclear etiology within the ﬁrst 100 days clinically sugges-
tive of GVHD, the impact of the histopathologic examination
is 18% (2 out of 11 patients in our cohort). The detailed
computational data are presented in the Supplemental
Appendix.
DISCUSSION
We found in our study that the onset of new cutaneous
eruptions after HCT led to initiation of several empiric ther-
apies to treat a wide array of diseases. In 56% of cases,
a biopsy changed the primary care team’s clinical diagnosis,
but affected the management in a far smaller percentage
(16%). In this relatively small number of cases, however, we
documented several important therapeutic changes.
Although in some ways these ﬁndings are similar to our
original institutional experience as described by Chren et al.
[4] several decades earlier, we observed differences between
the results from these 2 studies. First, we documented
a decrease in the percentage of nonspeciﬁc histologic results
(28%) when compared with the results from our previous
study (42%). Although we assume that such a change reﬂectsles Included in Model PPV NPV Sensitivity Speciﬁcity
rom T0, diagnosis, TBI, clinical
ression, type of graft, gender
24% 93% 63% 70%
17% 80% 28% 68%
iagnosis, clinical impression, gender 60% 86% 69% 80%
ody irradiation; T0, transplant day.
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alsomay be due to changes in histologic interpretation by the
dermatopathologists. Second, we also noted an increase in
the diagnosis of GVHD (from 9% to 35%, P < .001) and
systemic infection (from 2% to 4%, P ¼ .37). This result may
reﬂect the expansion of HCT to a broader range of patients,
including sicker, older patients with more advanced malig-
nant disease. The utility of the cutaneous biopsy remained
clinically signiﬁcant with respect to modifying therapy at
rates similar to our previous study.
A detailed search of the literature search revealed only
a small number of studies attempting to evaluate the utility
of skin biopsies. Kohler et al. [7] retrospectively attempted to
determine if the biopsy could predict the progression of
a rash to clinical grade II or higher GVHD; they concluded
that the skin biopsies were of limited value in this regard.
Although that study calls into question the utility of skin
biopsies, it does so in a completely different arena. We did
not evaluate the role of the skin biopsy as a prospective tool;
instead, we focused on its effectiveness as part of the diag-
nostic work-up. In the articles by Zhou et al. [6] and Kuy-
kendall et al. [8], samples obtained from biopsies within
3 weeks of HCT retrospectively were evaluated to determine
their diagnostic accuracy with respect to the syndrome of
GVHD. In both studies, skin biopsies were not deemed to be
effective tools because of the high degree of nonspeciﬁc
histologic ﬁndings. We noted that the majority of the biop-
sies (66%) performed in our study were obtained within the
ﬁrst 100 days after HCT; we also noted a high percentage
(28%) of nonspeciﬁc ﬁndings, conﬁrming the uncertainty
sometimes associated with this procedure. As our diagnostic
work up was based not only on the evaluation of GVHD but
also on the other myriad of cutaneous diseases that affect
HCT patients, we believe that this new information gleaned
from the biopsy altered the clinical approach and continue to
justify its usefulness.
We further attempted to reﬁne the utility of the skin
biopsy procedure by implementing a CART analysis. Our goal
was to determine if any combination of variables would
improve the diagnostic importance of the skin biopsy in the
patient’s management. Firoz et al. [9] reported the devel-
opment of a decision analysis model to predict the role of
skin biopsy to conﬁrm suspected acute GVHD in HCT recip-
ients. They concluded that in populations with a prevalence
of GVHD of 30% or greater, the best outcomes were obtained
without the use of a cutaneous biopsy. Our study, however,
did not focus solely on GVHD and, in fact, other entities were
detected in which the clinical management was altered
(Table 4).
Our study does have limitations. We were unable to
compile data regarding the frequency of cutaneous eruptions
that were investigated with a biopsy. Obviously, this situa-
tion reﬂects the clinical judgment and the inherent biases of
the transplant attending physician regarding the etiology of
the rash and the decision to obtain a biopsy. On the other
hand, our study includes all biopsies performed in a large
cohort of HCT recipients and a diverse group of dermatologic
diagnoses is represented. Other published studies focus
more on issues relating to GVHD and, as a result, it is difﬁcult
to draw comparisons with those reports.
A cutaneous biopsy may provide information that can be
used in conjunction with other clinical ﬁndings to supporta diagnosis of GVHD, or to establish an alternative cause of
the skin eruption. Because of the relative safety of skin biopsy
procedures and the known risks associated with immuno-
suppressive therapy used in themanagement of GVHD,many
clinicians continue to refer HCT patients who develop skin
eruptions (and have a broad differential diagnosis) to
dermatologists for a cutaneous biopsy procedure.
In conclusion, we found that cutaneous biopsies changed
the primary care team’s management in a sufﬁcient
percentage of patients to continue to support its use in HCT
recipients. We believe that the CART analysis should be
further validated in a prospective study and potentially can
help identify patients who are most likely to gain beneﬁt
from this minor surgical procedure. In the interim, we
recommend continuing the use of skin biopsy when appro-
priate in patients who have undergone HCT.ACKNOWLEDGMENTS
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